Therefore, our findings provide novel evidence that RPL8 may serve as a shared biomarker and a promising therapeutic target bridging inflammatory bowel disease and depression, although further mechanistic investigations are clearly warranted. The gene discussed is RPL8; the disease is depressive symptom measurement.